Adicet Bio, Inc. (ACET)
NCM · Healthcare · Biotechnology
$8.05
+6.62%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$75.3M
Shares Outstanding
9.3M
Exchange
NCM
Currency
USD
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -32.4M | -28.0M | -31.9M | -21.6M |
| Net Income | -31.2M | -26.9M | -30.5M | -20.2M |
| Diluted EPS | $-5.44 | $-4.64 | $-2.94 | $-1.88 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 25.0M | 0.00 | 0.00 | 0.00 |
| Operating Income | -72.6M | -132.6M | -127.6M | -122.1M |
| Net Income | -69.8M | -142.7M | -117.1M | -116.8M |
| Diluted EPS | $-27.20 | $-52.96 | $-21.28 | $-16.95 |